We are live on ! Find out more
LAB icon

Standard BioTools

155 hedge funds and large institutions have $372M invested in Standard BioTools in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 51 increasing their positions, 44 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

58% more call options, than puts

Call options by funds: $109K | Put options by funds: $69K

16% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 44

10% more capital invested

Capital invested by funds: $337M → $372M (+$34.9M)

0.95% more ownership

Funds ownership: 73.87%74.82% (+0.95%)

3% less funds holding

Funds holding: 160155 (-5)

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

Holders
155
Holders Change
-5
Holders Change %
-3.13%
% of All Funds
2.03%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
13
Increased
51
Reduced
44
Closed
17
Calls
$109K
Puts
$69K
Net Calls
+$40K
Net Calls Change
+$21K
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$101M +$1.94M +1,483,220 +2%
Viking Global Investors
2
Viking Global Investors
Connecticut
$76.2M
BlackRock
3
BlackRock
New York
$32.4M +$126K +96,158 +0.4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$22.4M +$346K +263,845 +2%
MCO
5
MAK Capital One
New York
$20.7M +$13.5M +10,334,384 +185%
LFCM
6
Long Focus Capital Management
Puerto Rico
$14.8M +$1.69M +1,292,804 +13%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$9.71M +$36.4K +27,783 +0.4%
State Street
8
State Street
Massachusetts
$8.32M +$133K +101,352 +2%
Morgan Stanley
9
Morgan Stanley
New York
$8.26M +$169K +129,142 +2%
HBWM
10
Hollow Brook Wealth Management
New York
$7.51M +$217K +165,428 +3%
Sumitomo Mitsui Trust Group
11
Sumitomo Mitsui Trust Group
Japan
$7.01M -$1.01M -773,708 -13%
NAMA
12
Nikko Asset Management Americas
New York
$7.01M -$1M -764,273 -12%
Neuberger Berman Group
13
Neuberger Berman Group
New York
$6.14M +$279K +212,605 +5%
TM
14
Tikvah Management
North Carolina
$4.62M -$1.96M -1,499,906 -30%
Barclays
15
Barclays
United Kingdom
$4.13M -$173K -131,741 -4%
AIM
16
ARK Investment Management
Florida
$3.93M -$175K -133,327 -4%
RA
17
Royce & Associates
New York
$3.65M +$220K +167,598 +6%
Northern Trust
18
Northern Trust
Illinois
$3.37M -$86.2K -65,786 -2%
Charles Schwab
19
Charles Schwab
California
$3.26M -$49.4K -37,718 -1%
NFGH
20
Nan Fung Group Holdings
Hong Kong
$2.45M
SPC
21
Slate Path Capital
New York
$2.1M
Millennium Management
22
Millennium Management
New York
$1.89M -$1.19M -907,230 -38%
PCP
23
Pacific Capital Partners
$1.72M -$65.5K -50,000 -4%
Goldman Sachs
24
Goldman Sachs
New York
$1.68M -$30.3K -23,118 -2%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$1.04M +$26.7K +20,401 +3%

LAB Hedge Fund Activity: Q3 2025 in Review

155 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2025, worth a combined $372M — up 10% from $337M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LAB and 13 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 51 added.

The largest buyer was MAK Capital One, adding an estimated $13.5M. The largest seller was Mirabella Financial Services, exiting entirely with an estimated $4.12M sold.

  • 155 institutional investors held Standard BioTools (LAB) as of Q3 2025, down from 160 in Q2 2025.
  • Funds reported $372M of Standard BioTools stock for Q3 2025, up 10% quarter-over-quarter.
  • 13 funds opened new Standard BioTools positions in Q3 2025 and 17 closed out, a net change of -4 holders.
  • The largest Standard BioTools buyer in Q3 2025 was MAK Capital One, an estimated $13.5M added.
  • The largest Standard BioTools seller in Q3 2025 was Mirabella Financial Services, an estimated $4.12M sold.

Based on aggregated 13F filings for Q3 2025.